Parkinson’s Disease Market to Witness Growth by 2032, Estimates DelveInsight | Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca

May 18 03:25 2023
Parkinson’s Disease Market to Witness Growth by 2032, Estimates DelveInsight | Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca
Parkinson’s Disease Market

(Albany, USA) DelveInsight’s “Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Parkinson’s Disease, historical and forecasted epidemiology as well as the Parkinson’s Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Parkinson’s Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Parkinson’s Disease market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Parkinson’s Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Parkinson’s Disease market.

 

Request for a Free Sample Report @ Parkinson’s Disease Market Forecast

 

Some facts of the Parkinson’s Disease Market Report are:

  • According to DelveInsight, Parkinson’s Disease market size was USD  2,800 million in 2021.
  • Leading Parkinson’s Disease companies working in the market are Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences,  Orpheris, Inc., Alkahest, Inc, and others.
  • Key Parkinson’s Disease Therapies expected to launch in the market are Rotigotine, extended-release microspheres, LY03003, LY3884961, Methylprednisolone, Sirolimus, VY-AADC02, ERE-120: AAV2-NTN, Liatermin, MEDI1341, and others.
  • In 2021, the total prevalent cases of PD  were the highest in the US, with  1,089,534 cases, and lowest in the UK with  148,955 cases.
  • There were 624,540 males and 464,994 females affected by PD in the United States in 2021, and it is estimated that the prevalence will increase by 2032.
  • Among EU5 countries, Germany had the highest number of prevalent cases of Parkinson’s Disease (419,602 cases) in 2021.
  • The Parkinson’s Disease Companies and academics that are working to assess challenges and seek opportunities that could influence Parkinson’s Disease R&D. The Parkinson’s Disease pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

Parkinson’s Disease Overview

Parkinson’s Disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine. Studies have shown that symptoms of Parkinson’s develop in patients with an 80 percent or greater loss of dopamine-producing cells in the substantia nigra. Normally, dopamine operates in a delicate balance with other neurotransmitters to help coordinate the millions of nerve and muscle cells involved in movement.

 

Learn more about Parkinson’s Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment

 

Parkinson’s Disease Market

The Parkinson’s Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Parkinson’s Disease market trends by analyzing the impact of current Parkinson’s Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Parkinson’s Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Parkinson’s Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Parkinson’s Disease market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Parkinson’s Disease Epidemiology

The Parkinson’s Disease epidemiology section provides insights into the historical and current Parkinson’s Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Parkinson’s Disease market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Parkinson’s Disease Epidemiology @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment

 

Parkinson’s Disease Drugs Uptake

This section focuses on the uptake rate of the potential Parkinson’s Disease drugs recently launched in the Parkinson’s Disease market or expected to be launched in 2019-2032. The analysis covers the Parkinson’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Parkinson’s Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Parkinson’s Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Parkinson’s Disease Pipeline Development Activities

The Parkinson’s Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Parkinson’s Disease key players involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the Parkinson’s Disease pipeline development activities @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment

 

Parkinson’s Disease Therapeutics Assessment

Major key companies are working proactively in the Parkinson’s Disease Therapeutics market to develop novel therapies which will drive the Parkinson’s Disease treatment markets in the upcoming years are Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences,  Orpheris, Inc., Alkahest, Inc, and others.

 

Learn more about the emerging Parkinson’s Disease therapies & key companies @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment

 

Parkinson’s Disease Report Key Insights

1. Parkinson’s Disease Patient Population

2. Parkinson’s Disease Market Size and Trends

3. Key Cross Competition in the Parkinson’s Disease Market

4. Parkinson’s Disease Market Dynamics (Key Drivers and Barriers)

5. Parkinson’s Disease Market Opportunities

6. Parkinson’s Disease Therapeutic Approaches

7. Parkinson’s Disease Pipeline Analysis

8. Parkinson’s Disease Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Parkinson’s Disease Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Parkinson’s Disease Competitive Intelligence Analysis

4. Parkinson’s Disease Market Overview at a Glance

5. Parkinson’s Disease Disease Background and Overview

6. Parkinson’s Disease Patient Journey

7. Parkinson’s Disease Epidemiology and Patient Population

8. Parkinson’s Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Parkinson’s Disease Unmet Needs

10. Key Endpoints of Parkinson’s Disease Treatment

11. Parkinson’s Disease Marketed Products

12. Parkinson’s Disease Emerging Therapies

13. Parkinson’s Disease Seven Major Market Analysis

14. Attribute Analysis

15. Parkinson’s Disease Market Outlook (7 major markets)

16. Parkinson’s Disease Access and Reimbursement Overview

17. KOL Views on the Parkinson’s Disease Market

18. Parkinson’s Disease Market Drivers

19. Parkinson’s Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting